HC Wainwright Has Lowered Expectations for vTv Therapeutics (NASDAQ:VTVT) Stock Price

vTv Therapeutics (NASDAQ:VTVT) had its price target dropped by equities researchers at HC Wainwright from $45.00 to $42.00 in a report released on Thursday, Marketbeat Ratings reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 18.74% from the company’s previous close.

Several other analysts have also issued reports on VTVT. BTIG Research boosted their price target on shares of vTv Therapeutics from $49.00 to $57.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Rodman & Renshaw initiated coverage on shares of vTv Therapeutics in a research note on Tuesday, June 30th. They issued a “buy” rating and a $67.00 price target for the company. Wall Street Zen raised shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Weiss Ratings raised shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Monday, May 18th. Finally, Zacks Research lowered shares of vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $55.83.

vTv Therapeutics Stock Performance

vTv Therapeutics stock opened at $35.37 on Thursday. The stock’s 50 day moving average price is $33.40 and its two-hundred day moving average price is $34.80. vTv Therapeutics has a 52-week low of $14.00 and a 52-week high of $44.00. The stock has a market capitalization of $139.36 million, a price-to-earnings ratio of -33.37 and a beta of 0.28.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.08). On average, equities research analysts forecast that vTv Therapeutics will post -2.19 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its stake in vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after buying an additional 12,896 shares during the last quarter. 683 Capital Management LLC purchased a new stake in shares of vTv Therapeutics during the 4th quarter worth approximately $731,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of vTv Therapeutics in the fourth quarter valued at $221,000. Hedge funds and other institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.